HDAC3 and Alzheimer disease: In another article, it was demonstrated that in the hippocampus of mice treated with oligomeric Aβ peptides, the administration of C-PC increased miRNA-335 levels with reduced apoptosis and attenuated the expression of HDAC3 [141], which represents a hopeful therapeutic target for AD treatment, because inhibition of HDAC3 in the hippocampal tissue reduced amyloid plaque load and Aβ levels and attenuated microglia activation in the brains of APP/PS1 mice [143].